ACP supports this measure because the current evidence supports the benefit of antiplatelet therapy in reducing complications in adults with CAD. The measure details reduce the administrative burden of documenting patient/medical reasons for withholding aspirin therapy. Lastly, the measure limits preventable adverse events by excluding patients who have already been prescribed warfarin therapy.

Date Reviewed: November 7, 2015